Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 28 January 2000:
Vol. 287. no. 5453, pp. 565 - 567
DOI: 10.1126/science.287.5453.565b
Prev | Table of Contents | Next

News of the Week

CLINICAL RESEARCH:
FDA Halts All Gene Therapy Trials at Penn

Eliot Marshal

The death of a volunteer in a gene therapy experiment at the University of Pennsylvania in September triggered a flood of publicity; now, the consequences have landed on researchers and other patients at Penn. On 19 January, the Food and Drug Administration (FDA) stopped all seven clinical trials run by Penn's Institute for Human Gene Therapy--perhaps the most respected and best funded center of its kind--after finding "serious deficiencies" in the way the institute monitors its trials. The FDA had already halted the trial in which 18-year-old Jesse Gelsinger died.

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)